Tibet Cheezheng Tibetan Medicine Co Ltd

002287.CS▼3

Cheezheng Tibetan Medicine Releases 2026 Interim Report with Net Profit of 371 Million Yuan

Cheezheng Tibetan Medicine released its 2026 interim report, with net profit attributable to the parent company of 371 million yuan. The company's total operating revenue was 978 million yuan, down 16.77 percent from the same period last year. Net cash inflow from operating activities was 239 million yuan, down 51.25 percent year on year. The company's latest gross margin was 82.08 percent, latest return on equity was 7.28 percent, and diluted earnings per share was 0.66 yuan.

002287.CS ▼

Jiemian·28dRead more →

002287.CS

Qizheng Tibetan Medicine's first-half net profit attributable to parent was 371 million yuan, up 3.6% year on year

Qizheng Tibetan Medicine released its 2026 interim report. Net profit attributable to the parent in the first half was 371 million yuan, up 3.6% year on year. Operating revenue was 978 million yuan, down 16.8% year on year. Net profit attributable to the parent excluding non-recurring items was 300 million yuan, up 3.6% year on year. Net operating cash flow was 239 million yuan, down 51.3% year on year. In the second quarter, operating revenue was 573 million yuan, down 25.8% year on year, and net profit attributable to the parent was 276 million yuan, down 2.3% year on year. The company said industry development conditions are relatively positive, with industrial policies and regulatory details from multiple ministries being rolled out one after another, providing support for the transformation and development of the traditional Chinese medicine industry. The company continues to maintain its leading position in the Tibetan medicine market.

002287.CS

财中社·29dRead more →

002287.CS▲

Qizheng Tibetan Medicine's first-half non-GAAP net profit rises 3.59%; interim dividend of 2.3 yuan per 10 shares proposed

Qizheng Tibetan Medicine disclosed its 2026 semi-annual report on the evening of August 21. In the first half, it achieved operating revenue of 978 million yuan, and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses of 300 million yuan, up 3.59% year on year. It also plans to distribute a cash dividend of 2.3 yuan per 10 shares, tax included, to all shareholders. Operating profit for the same period was 416 million yuan, and net profit attributable to shareholders of the listed company was 371 million yuan. Qizheng Tibetan Medicine is a leading modern Tibetan medicine enterprise. Its core product, Xiaotong Plaster, ranks first among external-use plasters in the skeletal and muscular system category of Chinese patent medicines, and its share of the Tibetan medicine market exceeds 50%.

002287.CS ▲

上海证券报·29dRead more →